Home › Products › Oncology › Hemlibra 105mg Injection
Hemlibra 105mg Injection
Salt Composition: EMICIZUMAB
- Manufacturer: ROCHE PRODUCTS INDIA PVT LTD
- Pack Size: 1 VIAL(s)
- Dosage Form: INJECTION
- Strength: 105MG
- Prescription Required
- Cold Chain
- Prepaid Only. Non-Returnable.
- Storage: Store in a refrigerator (2°C to 8°C) Do not freeze Protect the medicine from light and excessive moisture. Keep the medicine out of reach of children and pets If you missed the dosing schedule, inform your healthcare professional immediately and reschedule.
₹147175.00₹183967.86
Inclusive of all taxes
Product Introduction
Hemlibra 105mg Injection contains Emicizumab, a monoclonal antibody. It is indicated for patients with haemophilia A who have developed factor VIII inhibitors. It is also indicated for severe haemophilia A patients without factor VIII inhibitors (FVIII blood level less than 1%). Haemophilia A is an inherited condition characterised by deficiency of factor VIII, which is essential for blood clotting and haemostasis. Monoclonal antibodies are proteins that recognise and bind to specific targets within the body. This medicine reduces or prevents bleeding episodes in patients with this condition. Do not use Hemlibra 105mg Injection if you are allergic to Emicizumab or any other component of the formulation. Before initiating therapy, inform your doctor of all other medications you are taking. Report bleeding events to your physician immediately following administration of this medicine. This medicine is appropriate for all age groups. Do not administer this injection into areas where the skin is red, bruised, tender, hardened, or where moles or scars are present.
Uses
Hemophilia A
How it works
Emicizumab binds to activated factor IX and factor X to restore function to the coagulation cascade and promote hemostasis. It restores the function of missing activated factor VIII, which is needed for effective blood clotting. Its structure differs from factor VIII; therefore, the medicine is unaffected by factor VIII inhibitors.
How to Use
Hemlibra 105mg injection will be given under the skin (subcutaneous). Your doctor, nurse, or other healthcare professional will show you how to inject the medicine. Do not try to administer the medicine if you are well-trained. Your physician will decide the dose of the injection based on your disease condition and severity. The recommended places to give an injection are the front of the waist (lower abdomen), upper outer arms, or the front of the thighs. Use only recommended places for injection. For each injection, use a different area of the body than the one you used last time.
Side Effects
Side effects are unwanted symptoms caused by medicines. Even though all drugs cause side effects, not everyone gets them. Common Injection site reactions Joint pain Headache Serious Heart problems Muscle cramps and pain Blood clot Bleeding Destruction of red blood cells
Expert Tips
This medicine is given as a shot under your skin. It is usually injected into the upper outer arms, thighs, or stomach. Use a different body area each time you give yourself a shot. Keep track of where you give each shot to make sure you rotate body areas. Do not inject into skin areas that are tender, red, bruised, hard, or not intact, or into areas with moles or scars. Use a new needle and syringe each time you inject your medicine. Women should use an effective form of birth control to keep from getting pregnant. Tell your doctor right away if you think you have become pregnant. Your doctor will do lab tests at regular visits to check on the effects of this medicine. Keep all appointments
References
- Hemlibra 150 mg/mL Solution for Injection - Summary of Product Characteristics (SmPC) - (emc). www.medicines.org.uk. Published September 2022. Accessed May 10, 2023. http://www.medicines.org.uk/emc/product/9043/smpc
- Emicizumab Injection, Highlights of Prescribing Information, Revised 2017. Accessed May 10, 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761083s000lbl.pdf
- H.G. Watson, J.I.O. Craig, L.M. Manson, Blood disease, Davidsonâs Principles and Practice of Medicine, 22nd Edition, 2014, 989-1056.
- Le Quellec, Clinical Evidence and Safety Profile of Emicizumab for the Management of Children with Hemophilia A, Drug Design, Development and Therapy, 2020:14, https://www.dovepress.com/getfile.php?fileID=55818
Safety Advice
Pregnancy: unsafe Do not take Hemlibra 105mg Injection if you are pregnant because this may harm the unborn baby. Inform your physician if you are pregnant, suspecting pregnancy, or planning to get pregnant during the treatment. Use effective contraception during the treatment and for 6 months after the last dose.
Lungs: Consult your doctor It is unknown whether Hemlibra 105mg Injection can be used in patients with lung disorders. Consult your doctor if you have any lung diseases before starting the treatment.
Breastfeeding: unsafe Breastfeeding is not recommended in patients taking Hemlibra 105mg Injection because the medicine passes into the breast milk in small amounts and may harm your baby. Do not breastfeed during the treatment.
Disclaimer
The information provided on this page is intended for general informational purposes only and should not be considered as medical advice. Always consult a qualified healthcare professional before starting, stopping, or changing any medication. Self-medication can be harmful. Med For Rare does not endorse self-diagnosis or self-treatment.